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www.rbmonl ine .comEDITORIALHFEA reprieved – For the moment!In this issue, we publish three commentaries (English, 2013;
Franklin, 2013; Murdoch, 2013) on the value and future of
the UK Human Fertilisation and Embryology Authority
(HFEA). The HFEA was established by the 1990 Human Fertil-
isation and Embryology Act. It is ‘‘the UK’s independent reg-
ulator overseeing the use of gametes and embryos in
fertility treatment and research. The HFEA licenses fertility
clinics and centres carrying out in vitro fertilisation (IVF),
other assisted conception procedures and human embryo re-
search’’ (HFEA, 2013). In 2008 it had its powers modified,
and again came under scrutiny in July 2010 with the arrival
of a coalition Government determined to reduce the cost of
‘red tape’ – both financial and bureaucratic (Department of
Health, 2010). The Government issued a set of alternative
proposals for consultation between 28th June and 28th
September, 2012 (Department of Health, 2012), the three
options being:
Option 1 (the Government’s preferred option): All func-
tions of the HFEA and the Human Tissue Authority (HTA) to
transfer to the Care Quality Commission (CQC) with the
exception of HFEA research-related functions that would
transfer to the Health Research Authority (HRA); and the
HFEA and the HTA to be abolished.
Option 2: The transfer of functions and abolition as for
Option 1 but also that a limited number of functions might
transfer elsewhere.
Option 3: The HFEA and the HTA retain their functions
but deliver further efficiencies.
On January 25th this year, the results of this consultation
were announced together with the Government’s response
to them (Department of Health, 2013a). A total of 109 re-
sponses was received, most from organizations including
the HFEA, HTA, CQC and the HRA, but also from the British
Medical Association (BMA), the British Fertility Society
(BFS), the Academy of Medical Sciences (AMS), the Well-
come Trust, the Royal Society, and a number of Royal
Colleges, as well as private clinics and medical charities.
Of these, 75% disagreed with Option 1, only 8% agreeing
with it.
Primary amongst the reasons for this largely adverse
response was the observation that the HFEA and HTA
had developed considerable expertise in highly specialised1472-6483/$ - see front matter ª 2013, Reproductive Healthcare Ltd.
http://dx.doi.org/10.1016/j.rbmo.2013.02.010fields, as a result of which they were trusted and re-
spected by the regulated sectors. Almost half of respon-
dents also believed that the CQC was not well placed
currently to take on the HTA and HFEA functions without
detrimental effects on public confidence, the quality of
regulation and business efficiency. Many respondents
doubted that the anticipated savings would be forthcom-
ing and felt that too little regard had been given to tran-
sition costs (see also English, 2013; Franklin, 2013). In the
light of this overwhelming rejection of their reform agen-
da, the Government has accepted that both bodies should
continue – for the moment!
However, in its response the Government also states:
‘‘Many respondents do not regard a decision to retain the
bodies as an argument for maintaining the status quo but
see the need for review of how the bodies undertake their
functions.’’ It therefore proposes to ‘‘arrange an immediate
review of how the two bodies carry out their regulatory
functions, with a view to reducing regulatory burden. The
review will give serious consideration to the merger of the
HFEA and HTA. (Department of Health, 2013b)’’ This ‘inde-
pendent’ review will be undertaken by Justin McCracken,
Chief Executive of the Health Protection Agency since
2008 (Health Protection Agency, 2008), who will report by
April 2013. The HPA is another Government appointed body
set up in 2003 with a brief to ‘‘protect the public from
threats to their health from infectious diseases and environ-
mental hazards. It does this by providing advice and
information to the general public, to health professionals
such as doctors and nurses, and to national and local
government’’ (HPA, 2013).
What does all this really mean? Well, first the process of
consultation does seem to have worked once again. In its
conduct, it follows in a strong UK tradition, as Franklin
(2013) points out: ‘‘The involvement of the UK public in a
challenging and lengthy conversation about how best to reg-
ulate and govern human fertilisation and embryology is, like
much of the UK science that enabled IVF, comparatively
anomalous. The UK is unique in its ability both to have held
a lengthy public and parliamentary debate over the issues
raised by technologically assisted conception, and to have
successfully passed a comprehensive Act of ParliamentPublished by Elsevier Ltd. All rights reserved.
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IVF.’’
Second, the outcome of this consultation seems to repre-
sent on balance, a vote of confidence in the HFEA by its
users – doctors, patients and scientists. Indeed as English
(2013) says: ‘‘Those people working in the sector may not
always like the HFEA, or agree with its decisions. They
may believe it is too bureaucratic, makes too many de-
mands, gets involved in things it should not and is too
expensive. There are undoubtedly changes that are needed
but the question is whether abolition or reform is the better
alternative.’’ Clearly reform is preferred.
Third, and perhaps of greatest import, is the question as
to whether the proposed route to reform this time will be
more successful than previous attempts conducted in 2008
and in this recent consultation. In 2008, a Department of
Health proposal to merge the HFEA and the HTA for eco-
nomic reasons was thrown out by a joint committee of the
Lords and Commons. Then, as now, there was a very tight
time schedule and a restricted brief that constrained a dis-
passionate consideration of evidence. The same criticism
can be applied to the recent consultation. Thus in a period
of 4–5 years the HFEA will have been scrutinized both par-
tially and hastily three times. If this scrutiny had been
undertaken thoroughly the first time, we might have been
in a much more useful place now! A lot hangs on exactly
how McCraken is proposing to work, to whom will he listen,
and how tightly will he see his brief and his time scale. If he
is not truly independent but jumping to his Ministerial
masters, then I fear that we may be back in this same mess
before too long!
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